Motility-modifying drugs;Motilitatsmodifizierende pharmaka

Internist

Volumn 41, Issue 12, 2000, Pages 1318-1330

  Storr, M ^a   Allescher, H D ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ARGININE; ATROPINE; BOTULINUM TOXIN; CALCIUM ANTAGONIST; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; DILTIAZEM; DOMPERIDONE; ERYTHROMYCIN; ISOSORBIDE DINITRATE; LOXIGLUMIDE; METOCLOPRAMIDE; MORPHINE; NIFEDIPINE; OCTREOTIDE; OMEPRAZOLE; OPIATE; PHENOBARBITAL; PROKINETIC AGENT; SEROTONIN ANTAGONIST; SILDENAFIL; SPASMOLYTIC AGENT; SUCRALFATE; TRAZODONE; VERAPAMIL; VITAMIN D; GASTROINTESTINAL AGENT;

CONSTIPATION; ESOPHAGUS ACHALASIA; ESOPHAGUS DISEASE; ESOPHAGUS SPASM; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; HUMAN; REVIEW; STOMACH PARESIS; DRUG EFFECT; GASTROINTESTINAL TRANSIT;

GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; HUMANS;

EID: 0033635104     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050698     Document Type: Review

References (67)

1. Metoclopramide: Pharmacology and clinical application
2. Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia
3. Role of cholecystokinin as a regulator of solid and liquid gastric emptying in humans
4. Clinical and manometric effects of L-arginine in patients with chest pain and oesophageal motor disorders
5. Selective stimulation of colonictransit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans
6. Gastric myoelectric activity in patients with gastric outlet obstruction and idiopathic gastroparesis
7. Effects of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction
8. Effects of octreotide and erythromycin on gastric myoelectrical and motor activities in patients with gastroparesis
9. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial
10. Return of esophageal peristalsis after nifedipine therapy in patients with idiopathic esophageal achalasia
11. Cisapride: Influence on esophageal and gastric emptying and gastroesophageal reflux in patients with reflux esophagitis
12. Functional gut disorders: From motility to sensitivity disorders
13. Irritable bowel syndrome: A technical review for practice guideline development
14. Mebeverine alters small bowel motility in irritable bowel syndrome
15. The symptomatic effect of cisaprid in patients with irritable bowel syndrome and constipation
16. Treating the symptoms of gastroesophageal reflux disease: A double-blind comparison of omeprazole and cisapride
17. Second report of a multicenter study on electrical stimulation for the treatment of gastroparesis
18. Effect of cisapride, a new prokinetic agent, on esophageal motor function
19. Pathophysiology of achalasia
20. Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis
21. Effect of cisapride on secondary peristalsis in patients with gstroesophageal reflux disease
22. Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia
23. Cisapride versus ranitidine in the treatment of reflux esophagitis
24. Improvement of gastric emptying in diabetic gastroparesis by erythromycin
25. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients
26. Effects of trimebutine maleate on gastric motility in patients with gastric ulcer
27. Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome
28. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subject
29. Effect of cisapride on delayed gastric emptying in gastro-esophageal reflux disease
30. Selective 5-hydroxytryptamine antagonism: A role in irritable bowel syndrome and functional dyspepsia?
31. Gastric emptying in gastroesophageal reflux and the therapeutic role of prokinetic agents
32. Cisapride: A new class of prokinetic agent
33. Clinical pharmacology forum: Motility agents and the gastrointestinal tract
34. Cisapride vs metoclopramide. An acute study in diabetic gastroparesis
35. Symptoms and visceral perception in severe functional and organic dyspepsia
36. The physiology and pathophysiology of gastric emptying in humans
37. Transient lower esophageal sphincter relaxation
38. Tegaserod, a 5-HT4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome
39. Abnormal electroenzephalogram in irritable bowel syndrome
40. Gastrointestinal motor effects of erythromycin
41. Motility-modifying agents and management of disorders of gastrointestinal motility
42. Treatment of acute colonic pseudo-obstruction with neostigmine
43. Gastroparesis
44. Botulinum toxin for spastic gastrointestinal disorders
45. Treatment of achalasia with intrasphincteric injection of botulinum toxin. A pilot trial
46. Intrasphincteric botulinum toxin for the treatment of achalasia
47. Erythromycin, motilin, and the esophagus
48. Neostigmin for the treatment of acute colonic pseudo-obstruction
49. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
50. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome
51. Symptom relieve with amitryptiline in the irritable bowel syndrome
52. Amitryptiline improves the quality of life in patients with non ulcer dyspepsia
53. Colon motility and colo-anal reflexes in chronic idiopathic constipation. Effects of a novel enterokinetic agent cisapride
54. Objective and subjective results of a randomized, double-blind, placebo-controlled trial using cisapride to treat gastroparesis
55. Oral nifedipine in the treatment of noncardiac chest pain in patients with the nutcracker esophagus
56. Effects of misoprostol on postprandal segmental colonic motility in healthy volunteers and refractory chronic constipation
57. Tegaserod
58. Esophageal pharmacology and treatment of primary motility disorders
59. Current concepts on pathophysiology, diagnosis and treatment of diffuse esophageal spasm
60. Treatment of symptomatic diffuse esophageal spasm by injection of Botulinum toxin (BTX)
61. Pathophysiology and pharmacological treatment of gastroesophageal reflux disease
62. Visceral analgesics and functional dyspepsia: Have we found the Holy Grail?
63. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind, placebo-controlled study with mianserin
64. The role of nifedipine therapy in achalasia: Results of a randomized, double-blind, placebo-controlled study
65. Medical treatment of esophageal achalasia. Double-blind crossover study with oral nifedipine, verapamil, and placebo
66. Cisapride for the treatment of non-ulcer dyspepsia: A meta-analysis of randomized controlled trials
67. Alosetron retards small bowel and overall colonic transit in diarrhoea-predominant irritable bowel syndrome